Engflag

Staloral

Quick links to important sections

Staloral

Staloral_DE

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Staloral

What is Staloral? (Identity and Purpose)

Property Description
Active ingredient Standardized Allergen Extracts (Dermatophagoides pteronyssinus, D. farinae)
Form Aqueous Sublingual Solution (Oral Drops)
Pharmacological class Immunomodulator, Hyposensitisation Agent
Common use Modifies the underlying cause of perennial Type I allergies
Origin Biologically derived (Natural source material)

What Type of Medicine is Staloral?

Staloral is a prescription-only medicinal product classified as an Allergen Immunotherapy (AIT) agent, utilizing the Sublingual Immunotherapy (SLIT) route of administration. Pharmacologically, it is designated as an Immunomodulator or Hyposensitisation Agent because its fundamental action is directed at regulating the immune system's response to specific substances. This approach is clinically recognized by health authorities as the only treatment modality capable of altering the natural course of allergic disease. This means that unlike common symptomatic medications, this treatment focuses on achieving long-term change in the body's allergic reaction pattern. Staloral is manufactured by Stallergenes Greer, defining its specific brand identity within the high-dose SLIT market.

Composition and Form: The Allergen Extract

The active principles of Staloral are Standardized Allergen Extracts derived biologically from House Dust Mites, specifically including the two major species: Dermatophagoides pteronyssinus and Dermatophagoides farinae. This dual-species composition is a differentiating factor, aiming for broad coverage against key domestic allergens. The product is manufactured as an Aqueous Sublingual Solution, a water-based vehicle designed for placement under the tongue for absorption through the oral mucosa. As a Combination Product, the standardized allergen concentration is often expressed in the Index of Reactivity (IR) unit, reflecting its measured allergenic strength.

General Purpose: Modifying the Allergic Response

The core therapeutic purpose of Staloral is the sustained reduction of allergic hypersensitivity through the induction of immunological tolerance to House Dust Mites. This treatment aims to shift the body's defensive reaction away from the detrimental allergic cascade and toward a non-allergic response. By operating as a Hyposensitisation Agent, the general long-term benefit is the potential to provide durable relief from perennial allergy symptoms, such as persistent allergic rhinitis or mild-to-moderate allergic asthma, which reflects a lasting modification of the disease’s mechanism.

Regulatory References

  1. Mite Extract Composition (NIBSC/WHO)

What side effects are possible with Staloral?

Possible side effects and safety information

The safety profile of this standardized allergen extract, as documented in official regulatory sources, is structured around the potential for allergic reactions to the administered allergen. Adverse reactions are formally classified by frequency and system-organ class.

Frequency-Classified Adverse Reactions

The majority of documented effects are categorized as Very Common or Common and are typically localized to the mouth and throat (e.g., oral pruritus, pharyngeal edema) or involve the gastrointestinal system (e.g., nausea, abdominal pain). Uncommon effects include headache, dizziness, and conjunctivitis. The frequency and intensity of adverse reactions are officially noted to be highest during the initial dose-escalation phase and generally lessen during the long-term maintenance period.

Serious Adverse Reactions and Safety Constraints

While rare, regulatory documents acknowledge the potential for serious adverse reactions, including Anaphylactic Reaction and Severe Asthma Exacerbation. This risk establishes specific constraints on use.

Safety Domain Regulatory Statement
Serious Reactions Potential for Anaphylactic Reaction, Severe Asthma Exacerbation, and Laryngeal Edema are documented.
Contraindications The product is formally restricted from use in individuals with uncontrolled or severe asthma or active autoimmune diseases.
Concomitant Safety Use with beta-blockers is noted as a safety restriction due to its potential to reduce the efficacy of emergency treatment for systemic reactions.

This structure ensures the risks are formally communicated, distinguishing between the high frequency of expected local reactions and the low but critical risk of systemic events that determine patient eligibility.

Overdose and Emergency Response

Overdose and when to seek help

The official overdose profile for this sublingual allergen extract is defined by the risk of severe systemic allergic reactions resulting from excessive exposure to the active ingredient.

Overdose Scope

Property Official Regulatory Documentation Statement
Documented overdose presentations: Overdose may cause severe systemic allergic reactions, including angioedema (swelling of face/throat), difficulty breathing, changes in voice, and cardiac symptoms like hypotension (low blood pressure).
Physiological systems affected (as stated in label): Respiratory system (airway compromise, severe asthma exacerbation), cardiovascular system (hypotension, palpitations), and mucous membranes (swelling).
Dose-related or exposure-related factors (if applicable): The risk of a severe reaction is associated with excessive dosage or exposure to high concentrations of the allergen extract.
Population-specific overdose notes (if applicable): The product is contraindicated and poses an increased risk of severe outcomes in patients with severe, unstable, or uncontrolled asthma.
Emergency-response statements (as written in official documents): Emergency equipment and personnel trained in the management of severe allergic reactions must be available during the initial dose. Patients should be instructed on the emergency use of auto-injectable epinephrine.
When immediate medical help is required (label-derived phrasing only): Patients must seek immediate medical attention and discontinue treatment upon the onset of any sign of a severe systemic reaction or after the administration of epinephrine.

Overdose Classifications (high-level)

Property Official Regulatory Documentation Statement
Severity classification (as defined in official documents): The reaction is classified as a severe allergic reaction, including anaphylaxis, which may be life-threatening.
Regulatory basis (EMA / FDA / etc.): FDA and EMA-aligned prescribing information.
Overdose-context constraints (as defined in official documents): The initial dose must be administered under medical supervision, with the patient monitored for at least 30 minutes.

Resulting Overdose Structure

Official overdose statements:

  • Overdose may lead to severe systemic reactions, including anaphylaxis and symptoms like throat swelling or hypotension.
  • Patients must seek immediate medical attention and stop treatment if a severe systemic reaction occurs.
  • No specific antidote is documented for the allergen; management is symptomatic and supportive.

Connection to the overall overdose profile (2–4 sentences): Regulatory documents define the overdose profile by linking excessive allergen exposure to the risk of an acute, severe immune-mediated response. The official structure mandates that the potential for a life-threatening anaphylaxis dictates the immediate response, requiring prompt medical intervention and the use of emergency medication. This profile reinforces the need for medical supervision during the initial administration due to the high-risk nature of the potential reaction.

Therapeutic Uses of Staloral

What Staloral Treats: Main Uses and Benefits

Staloral is generally used to help manage symptoms associated with Type I allergic conditions caused by a verified allergy to House Dust Mites (Dermatophagoides pteronyssinus and D. farinae). The treatment is relevant for easing the overall discomfort associated with the underlying allergic response. This therapy is utilized across therapeutic domains where long-term symptomatic support is appropriate, particularly when additional support is needed for ongoing allergy management.

The therapy is commonly used for conditions presenting with chronic rhinitis and rhinoconjunctivitis, including Perennial Allergic Rhinitis, Allergic Rhinoconjunctivitis, and mild-to-moderate Allergic Asthma linked to house dust mite sensitivity. The management of chronic symptoms helps ease the overall symptom load, which may assist with providing supportive relief when symptoms interfere with routine activities. This approach is often used when symptoms intensify and supportive relief is needed, particularly in scenarios where symptomatic medications alone provide inadequate management.

Quick Fact: Supports Management of Chronic Nasal Congestion

This therapy is commonly used to help manage the persistent nasal blockage and continuous runny nose associated with year-round house dust mite exposure.

Regulatory References

  1. Immunotherapy of house dust mite allergy - NIH

Eligibility and Restrictions for Use

Eligibility Scope

The medicine is approved for use in adults and adolescents and in children aged 5 years and older who have confirmed house dust mite allergy. Use is not recommended in children under 5 years of age or in older adults over 65 years due to limited clinical data. No specific limitations are documented for patients with hepatic or renal impairment.

Populations for whom use is contraindicated

Staloral is strictly contraindicated for patients with several conditions, including severe and/or unstable asthma, active autoimmune diseases, immunodeficiencies, and malignant neoplastic disease. Use is also prohibited in patients with severe inflammation of the oral mucosa (such as oral wounds or ulcers) or known hypersensitivity to any inactive ingredients. Patients taking beta-blockers require restricted use due to the risk of unresponsiveness to emergency allergy treatment.

Pregnancy and Lactation Eligibility Status

Initiation of treatment is not recommended during pregnancy. If a patient becomes pregnant while undergoing well-tolerated treatment, continuation is determined after careful evaluation. Treatment may generally be started or continued while breastfeeding (lactation), although specific clinical data in this population may be limited.

Eligibility-Related Restrictions

Treatment must be temporarily interrupted following oral surgery or tooth extraction until the oral cavity has fully healed.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Staloral (House Dust Mite Allergen Extract) is defined by pharmacodynamic constraints related to its function as an immunomodulator, rather than the pharmacokinetic interactions common to small-molecule drugs. Official prescribing information states that no formal pharmacokinetic studies have been conducted because such interactions are not expected.

Documented Interaction Restrictions

Interacting Substance/Class Regulatory Restriction Type Rationale (Official Statement)
Immunosuppressive Treatments Restricted Co-administration Potential for interference with the desired immunological effect of the immunotherapy.
beta-Blockers (Beta-adrenergic antagonists) Caution/Use-Restricted May reduce the efficacy of epinephrine (adrenaline), the necessary treatment for a severe systemic allergic reaction.
Live Attenuated Vaccines Timing Separation Required Mandatory interruption or separation of Staloral administration is specified around vaccination schedules.

Co-administration with systemic immunosuppressive treatments is restricted due to the potential for interference with the underlying immune response. Additionally, the label documents that concomitant use of symptomatic anti-allergic treatments (e.g., antihistamines) may potentially increase the patient's tolerance level to the therapy. No formal interactions with food, alcohol, or herbal products are reported in official regulatory documents. Furthermore, patients with pre-existing cardiovascular conditions are noted to have an increased risk profile concerning the potential management of a systemic allergic reaction during treatment.

Mechanism of Action

How Staloral Works: The Mechanism of Action

The action of Staloral, an Allergen Immunotherapy (AIT) agent, is defined by the targeted, long-term reprogramming of the adaptive immune system to induce tolerance.

Cellular Reprogramming and Immune Tolerance Induction

The sublingual extract targets specialized Dendritic cells in the oral lining, acting as an inducer to reprogram T-lymphocytes into allergen-specific Regulatory T cells (Tregs). This mechanism establishes a persistent, active immunological memory that suppresses Type I hypersensitivity signaling at the cellular level.

Cytokine Shift and Antibody Desensitization

The expanded Tregs produce immunosuppressive signaling molecules like Interleukin-10 (IL-10) and shift the B-cell response via isotype switching from allergic IgE to protective IgG4 blocking antibodies. This dual-action mechanism structurally limits the immediate IgE-mediated trigger and leads to the systemic desensitization of mast cells and basophils, supporting a regulated state within the allergic pathways.

Multi-Species Cascade Initiation

The combination of both D. pteronyssinus and D. farinae extracts initiates the Treg/IgG4 induction cascade against both major species of house dust mite allergen. This contributes to a broader scope of immunological hyporesponsiveness across both targeted allergen species.

Dosage and Administration Information

The use of Staloral is governed by a long-term, standardized Sublingual Immunotherapy (SLIT) regimen designed to deliver a specific dose of allergen extract daily. The regimen is divided into two sequential phases—titration and maintenance—and is intended for consistent self-administration by the patient in the outpatient setting. The dosage strength is measured in the Index of Reactivity (IR), a biological unit of potency.

Official Administration Guidelines

Instruction Detail
Route of administration: Sublingual (under the tongue) using an aqueous solution (oral drops).
Dosing schedule: Initial Titration Phase of dose escalation, followed by a long-term Maintenance Phase at a standardized daily dose of 300, IR.
Timing in relation to meals: Once daily, often advised to be administered in the morning and before breakfast.
Age-group rules: The standardized regimen is used for both adults and pediatric patients (typically 5 years and older).
Missed-dose rules: Following prolonged interruption (e.g., exceeding seven days), a healthcare provider should be consulted, as a return to the titration phase may be necessary.
Special conditions: Administration must be temporarily suspended in the presence of oral mucosal lesions or during acute febrile illness.

Resulting Procedural Structure

Official step sequence:

  • The required volume of solution is dispensed using the calibrated pump.
  • The dose must be placed and held under the tongue for approximately one to two minutes.
  • The patient then swallows the solution.
  • Food or drink should be avoided for a short period immediately following administration.

Connection to the Overall Use Protocol

These official instructions establish a structured, daily protocol that is necessary to deliver the standardized allergen dose consistently over a multi-year period. This regimen dictates the specific sublingual method and required contextual timing, ensuring the product is used exactly as documented in the regulatory prescribing information.

Recent Clinical Evidence

The research evidence for Staloral (House Dust Mite extract) is derived primarily from structured randomized, double-blind, placebo-controlled trials (DBPC-RCTs) and real-world observation. These studies were conducted to explore how the condition's manifestations and patient experiences evolve during the period of observation. The analysis focuses on the study design and what has been observed so far.

Evidence for Perennial Allergic Rhinitis and Rhinoconjunctivitis

Research for chronic nasal and eye allergies relies heavily on DBPC-RCTs and systematic reviews. Research examined how symptoms evolved by tracking patient-reported discomfort (sneezing, congestion) and the need for symptom-targeted drugs. Findings describe patterns observed in these studies where measurements of patient symptoms and medication use were recorded across treatment periods of one to three years. However, follow-up durations were limited in some controlled trials, and the established correlation between immunological changes and patient-reported benefit remains uncertain.

Evidence for Mild-to-Moderate Allergic Asthma

Clinical evaluation in patients with house dust mite-induced asthma involved pivotal Phase III trials and long-term observational studies. Studies monitored outcomes related to episodic or acute changes, specifically tracking the frequency of asthma exacerbations and measurements of overall asthma control. Real-world evidence contributes to understanding long-term disease management, where data were recorded concerning the evolution of asthma severity and the needed intensity of treatment over periods extending up to eight years.

Research Gaps and Special Populations

Studies explored whether the observed patterns continued after the treatment was stopped, though long-term effects are not fully established across all settings. Research was also evaluated in distinct groups, including children (as young as five years old) and adults with comorbid conditions (rhinitis and asthma). Data for certain groups remain insufficient, highlighting areas where more research is needed to ensure broad context.

Key Studies & References Authorised Allergens for Sublingual Immune Therapy (Regulatory context, PEI/EMA)

Frequently Asked Questions (FAQ)

Common questions about Staloral (FAQ)

Q: Is it possible to take Staloral at night instead of in the morning?

Official administration guidelines generally recommend taking the dose in the morning before breakfast. This is typically advised to allow for the observation of any potential immediate allergic reactions during the patient's waking hours. While there is no explicit regulatory statement prohibiting night-time administration, the precise timing should be discussed with a healthcare provider.

Q: What is the correct way to get rid of the medicine if I have leftovers?

According to official product information, Staloral must not be placed in the wastewater or regular household trash. Patients are required to follow local regulations for pharmaceutical waste. Information on the specific procedure for disposing of unused or expired medicine is available from a pharmacist or local waste authority.

Q: What are the common side effects of Staloral that affect the skin?

The most frequently reported side effects are localized to the mouth, throat, and digestive system. However, official product information indicates that skin reactions, such as hives (urticaria), generalized itching (pruritus), or swelling (edema), are documented as uncommon side effects. Any concerning skin reactions should be brought to the attention of a healthcare provider.

Q: What do I need to do if I accidentally take two doses in one day?

Official regulatory documents caution that taking more than the prescribed dose may increase the risk of side effects, including the potential for a severe systemic reaction. In this event, patients are advised to seek immediate medical attention or contact a poison control center for guidance.

How should Staloral be stored and disposed of?

Storage and Disposal Requirements

Staloral sublingual solution must be stored under specific conditions to maintain the stability of the allergen extracts.

Storage Conditions

The product must be stored in a refrigerator at a temperature between 2 C and 8 C and must not be frozen. Keep the solution in its original pack and in an upright position to protect it from moisture and light. The medicine must be kept out of the reach of children.

Stability and Disposal

The solution must be discarded 4 months after opening the bottle, regardless of the amount remaining. Unused or expired Staloral must not be disposed of in the wastewater or household waste. Disposal must follow local regulations for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagRussia

Equivalent of Staloral found in:

A-Z Index: